STOCK TITAN
  1. Home
  2. News
  3. SIGA

SIGA Technologies Inc - SIGA STOCK NEWS

Welcome to our dedicated news page for SIGA Technologies (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on SIGA Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SIGA Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SIGA Technologies's position in the market.

News
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®
Rhea-AI Summary
SIGA Technologies, Inc. (NASDAQ: SIGA) announced an amendment to its international promotion agreement with Meridian Medical Technologies, Inc., focusing on promoting oral TPOXX®. The agreement aims to enhance promotion activities and maintain key customer relationships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.78%
Tags
none
-
News
SIGA Names Larry Miller General Counsel
Rhea-AI Summary
SIGA Technologies, Inc. appoints Larry Miller as general counsel, bringing over twenty years of biopharmaceutical industry experience to drive the company's success and growth strategies. Miller's expertise in commercial businesses, mergers and acquisitions, and corporate governance will aid in expanding SIGA's global reach and maximizing benefits for patients, customers, and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
none
-
News
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023
Rhea-AI Summary
SIGA Technologies, Inc. (SIGA) reported strong financial results for 2023, with $131 million in product sales and $84 million in pre-tax operating income. The company declared a special cash dividend of $0.60 per share, showing a significant increase over the previous year. SIGA's revenue growth, international sales, and diversification efforts highlight its robust business model and sector leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.24%
Tags
earnings
News
SIGA Declares Special Cash Dividend of $0.60 Per Share
Rhea-AI Summary
SIGA Technologies, Inc. (SIGA) declares a special cash dividend of $0.60 per share, a 33% increase over the previous year's dividend. The dividend will be paid on April 11, 2024, to shareholders of record as of March 26, 2024, showcasing the company's strong financial performance and commitment to generating shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.79%
Tags
dividends
-
News
SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
SIGA Technologies, Inc. (SIGA) will host a webcast and conference call on March 12th, 2024, to provide a business update. Dr. Diem Nguyen, CEO, and Daniel Luckshire, CFO, will participate. The call will be accessible via webcast and phone. Replay options will also be available for two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
conferences earnings
-
News
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer
Rhea-AI Summary
SIGA Technologies, Inc. announced the appointment of Diem Nguyen, Ph.D., as the new CEO, effective January 27, 2024. Dr. Nguyen will lead the company's efforts in developing antiviral therapies for infectious diseases, representing SIGA in engagements with government partners, and securing new contracts and partnerships. With a background in biotechnology and pharmaceuticals, Dr. Nguyen's appointment signals the company's commitment to advancing global health solutions and addressing unmet needs in healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
management
News
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023
Rhea-AI Summary
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA) reported financial results for Q3 2023, including U.S. government orders for $113M of Oral TPOXX and $25M of IV TPOXX. European Commission signed a contract with anticipated initial orders of $18M for Oral TPOXX. Q3 2023 revenues were $9.2M, with a net loss of $0.4M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.59%
Tags
earnings
-
News
SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results
Rhea-AI Summary
SIGA Technologies, Inc. will host a webcast and conference call for a business update on November 7th, 2023. Participants can access the call via dial-in or live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries
Rhea-AI Summary
SIGA Technologies announces the creation of a joint procurement mechanism for oral TPOXX by the European Commission's DG HERA, with an anticipated initial order value of $18 million. Total TPOXX orders in 2023 expected to reach approximately $164 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
News
Meridian Medical Technologies, LLC, and the European Commission’s DG HERA Sign Agreement for 13 Countries From the EEA to Purchase Tecovirimat SIGA
Rhea-AI Summary
Meridian Medical Technologies signs framework contract with the European Commission for the procurement of Tecovirimat SIGA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
Stock SIGA logo
SIGA Technologies Inc

Nasdaq:SIGA

SIGA Rankings

#2786 Ranked by Market Cap
#4542 Ranked by Stock Gains
#2147 Ranked by Dividends

SIGA Stock Data

626.32M
40.25M
9.4%
49.43%
7.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About SIGA

at siga, we specialize in developing therapeutic solutions for some of the most lethal pathogens – smallpox, ebola, dengue, lassa fever and other dangerous viruses. our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats.